The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 553-558

  Turgeon, Sarah M ^a   Auerbach, Eliza A ^a   Heller, Michael A ^a  

^a AMHERST COLLEGE   (United States)

Author keywords

Latent inhibition; Phencyclidine; Schizophrenia

Indexed keywords

PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TASTE AVERSION;

ANIMALS; AVOIDANCE LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; TASTE;

EID: 0032100464     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00026-4     Document Type: Article

References (42)

1. Adler L., Rose G., Freedman R. Neurophysiological studies of sensory gating in rats. Effects of amphetamine, phencyclidine, and haloperidol Biol. Psychiatry. 21:1986;787-798.
2. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084.
3. Angrist B. Amphetamine psychosis. Clinical variations of the syndrome Cho A.K., Segal D.S. Amphetamine and its analogues. 1994;387-414 Academic Press, San Diego.
4. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79:1983;565-575.
5. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Comp. Psychiatry. 2:1961;269-280.
6. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176:1988;598-606.
7. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
8. Cornblatt B.A., Lenzenweger M.F., Dworkin R.H., Erlenmeyer-Kimling L. Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr. Bull. 11:1985;397-408.
9. Deutch A.Y., Tam S.-Y., Freeman A.S., Bowers M.B., Roth R.H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine. Contrasting pattern to striatal response Eur. J. Pharmacol. 134:1987;257-264.
10. Dunn L.A., Atwater G.E., Kilts C.D. Effects of antipsychotic drugs on latent inhibition. Sensitivity and specificity of an animal behavioral model of clinical drug action Psychopharmacology (Berlin). 112:1993;315-323.
11. Ellenbroek B.A., Cools A.R. Animals models with construct validity for schizophrenia. Behav. Pharmacol. 15:1990;469-490.
12. Ellenbroek B.A., Geyer M.A., Cools A.R. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J. Neurosci. 15:1995;7604-7611.
13. Ellenbroek B.A., Knobbout D.A., Cools A.R. The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology (Berlin). 129:1997;112-120.
14. Feldon J., Weiner I. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli Biol. Psychiatry. 29:1991;635-646.
15. Gao X.-M., Shirakawa O., Du F., Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol. 241:1993;7-15.
16. Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., Gray J.A. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berlin). 107:1992;425-430.
17. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633:1994;337-342.
18. Janowsky D.S., Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berlin). 65:1979;73-77.
19. Javitt D.C. Negative schizophrenic symptomotology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry. 9:1987;12-35.
20. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
21. Lubow R.E. Latent inhibition. Psychol. Bull. 79:1973;398-407.
22. Lubow R.E., Gerwirtz J.C. Latent inhibition in humans. Data, theory, and implications for schizophrenia Psychol. Bull. 117:1995;87-103.
23. Lubow R.E., Weiner I., Schlossberg A., Baruch I. Latent inhibition and schizophrenia. Bull. Psychon. Soc. 25:1987;464-467.
24. Luby E.D., Cohen B.D., Rusenbaum G., Gottieb J.S., Kelly R. Study of a new schizophreniamimetic drug - Sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369.
25. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
26. McCullough L.D., Salamone J.D. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res. 577:1992;1-9.
27. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine. A new model of schizophrenia Br. J. Pharmacol. 116:1995;2531-2537.
28. Ogawa S., Okuyama S., Araki H., Otomo S. Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur. J. Pharmacol. 263:1994;9-15.
29. Okuyama S., Ogawa S., Nakazato A., Tomizawa K. Effect if NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci. Lett. 189:1995;60-62.
30. Parker L.A. Rewarding drugs produce taste avoidance but not taste aversion. Neurosci. Biobehav. Rev. 19:1995;143-151.
31. Solomon P.R., Crider A., Winkelman J.W., Turi A., Kamer R.M., Kaplan L.J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity. Relationship to schizophrenic attention disorder Biol. Psychiatry. 16:1981;519-537.
32. Sonders M.S., Keana J.F.W., Weber E. Phencyclidine and psychotomimetic sigma opiates. Recent insights into their biochemical and physiological sites of action Trends Neurosci. 11:1988;37-40.
33. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
34. Walker E., Harvey P. Positive and negative symptoms in schizophrenia. Attentional performance correlates Psychopathology. 19:1986;294-302.
35. Weiner I. Neural substrates of latent inhibition. The switching model Psychol. Bull. 108:1990;442-461.
36. Weiner I., Feldon J. Phencyclidine does not disrupt latent inhibition in rats. Implications for animals models of schizophrenia Pharmacol. Biochem. Behav. 42:1992;625-631.
37. Weiner I., Feldon J., Gal G. The role of the nucleus accumbens subterritories in latent inhibition. Soc. Neurosci. Abstr. 23:1997;1120.
38. Weiner I., Izzraeli-Telerant A., Feldon J. Latent inhibition is not affected by acute of chronic administration of 6 mg/kg dl-amphetamine. Psychopharmacology (Berlin). 91:1987;345-351.
39. Weiner I., Lubow R.E., Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav. 30:1988;871-878.
40. Weiner I., Lubow R.E., Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berlin). 83:1984;194-199.
41. Weiner I., Lubow R.E., Feldon J. Chronic amphetamine and latent inhibition. Behav. Brain Res. 2:1981;285-286.
42. Weiner I., Shofel A., Feldon J. Disruption of latent inhibition by low dose of amphetamine is antagonized by haloperidol and apomorphine. J. Psychopharmacol. 4:1990;255.